1. Hershey AD. Migraine. Kliegman RM, Stanton BF, St. Geme JW, Schor NF, Behrman RE, editors. Nelson textbook of pediatrics. 20th ed. Philadelphia: Elsevier/Saunders, 2011;:2040–2045.
2. Split W, Neuman W. Epidemiology of migraine among students from randomly selected secondary schools in Lodz. Headache 1999;39:494–501.
3. Lee LH, Olness KN. Clinical and demographic characteristics of migraine in urban children. Headache 1997;37:269–276.
4. Ben-Menachem E, Henriksen O, Dam M, Mikkelsen M, Schmidt D, Reid S, et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996;37:539–543.
5. Faught E, Wilder BJ, Ramsay RE, Reife RA, Kramer LD, Pledger GW, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group. Neurology 1996;46:1684–1690.
6. Privitera M, Fincham R, Penry J, Reife R, Kramer L, Pledger G, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Topiramate YE Study Group. Neurology 1996;46:1678–1683.
7. Sharief M, Viteri C, Ben-Menachem E, Weber M, Reife R, Pledger G, et al. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res 1996;25:217–224.
8. Tassinari CA, Michelucci R, Chauvel P, Chodkiewicz J, Shorvon S, Henriksen O, et al. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 1996;37:763–768.
9. Fritz N, Glogau S, Hoffmann J, Rademacher M, Elger CE, Helmstaedter C. Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy Behav 2005;6:373–381.
10. Tang Y, Xia W, Yu X, Zhou B, Wu X, Lui S, et al. Altered cerebral activity associated with topiramate and its withdrawal in patients with epilepsy with language impairment: an fMRI study using the verb generation task. Epilepsy Behav 2016;59:98–104.
11. Coppola F, Rossi C, Mancini ML, Corbelli I, Nardi K, Sarchielli P, et al. Language disturbances as a side effect of prophylactic treatment of migraine. Headache 2008;48:86–94.
12. Bae SY, Lim SS, Lee JH. Test of problem solving. Seoul: Seoul Community Rehabilitation Center, 2005.
13. Kim SJ, Kim MY, Choi YM, Song MK. Effects of topiramate on language functions in newly diagnosed pediatric epileptic patients. Pediatr Neurol 2014;51:324–329.
14. Kim YT, Hong GH, Kim KH. Content and reliability analyses of the receptive and expressive vocabulary test (REVT). Commun Sci Disord 2009;14:34–45.
15. Kim YT, Shin MJ. Urimal Test of Articulation and Phonology (U-TAP). Seoul: Hakjisa, 2004.
16. Silberstein SD. Topiramate in migraine prevention. Headache 2005;45(Suppl 1): S57–S65.
17. Storey JR, Calder CS, Hart DE, Potter DL. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 2001;41:968–975.
18. Brandes JL. Practical use of topiramate for migraine prevention. Headache 2005;45(Suppl 1): S66–S73.
19. Winner P, Pearlman EM, Linder SL, Jordan DM, Fisher AC, Hulihan J, et al. Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial. Headache 2005;45:1304–1312.
20. Lakshmi CV, Singhi P, Malhi P, Ray M. Topiramate in the prophylaxis of pediatric migraine: a double-blind placebo-controlled trial. J Child Neurol 2007;22:829–835.
21. Fallah R, Akhavan Karbasi S, Shajari A, Fromandi M. The efficacy and safety of topiramate for prophylaxis of migraine in children. Iran J Child Neurol 2013;7:7–11.
22. Diamond M, Dahlöf C, Papadopoulos G, Neto W, Wu SC. Topiramate improves health-related quality of life when used to prevent migraine. Headache 2005;45:1023–1030.
23. Bussone G, Diener HC, Pfeil J, Schwalen S. Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials. Int J Clin Pract 2005;59:961–968.
24. Shaygannejad V, Janghorbani M, Ghorbani A, Ashtary F, Zakizade N, Nasr V. Comparison of the effect of topiramate and sodium valporate in migraine prevention: a randomized blinded crossover study. Headache 2006;46:642–648.
26. Ijff DM, Aldenkamp AP. Cognitive side-effects of antiepileptic drugs in children. Handb Clin Neurol 2013;111:707–718.
27. Baeta E, Santana I, Castro G, Gonçalves S, Gonçalves T, Carmo I, et al. Cognitive effects of therapy with topiramate in patients with refractory partial epilepsy. Rev Neurol 2002;34:737–741.
28. de Araujo Filho GM, Pascalicchio TF, Lin K, Sousa PS, Yacubian EM. Neuropsychiatric profiles of patients with juvenile myoclonic epilepsy treated with valproate or topiramate. Epilepsy Behav 2006;8:606–609.